Adagene
4 known investors
Adagene is a clinical-stage immunotherapy company that uses computational biology and artificial intelligence to discover and design therapeutic antibodies for cancer treatment. The company's platform generates novel antibodies aimed at improving safety and efficacy in precision-guided antibody-drug conjugates and other therapeutic approaches.
AI & Machine LearningBiotech
Investors · 4
In the news
- Guggenheim reiterates Adagene stock Buy rating on competitor shift By Investing.comza.investing.com · 2026
- Guggenheim raises Adagene stock price target on cancer drug data By Investing.cominvesting.com · 2026
- Adagene's $70M Raise Fuels Pipeline Hopes—But Is the Bull Case Already Priced In?ainvest.com · 2026
- Adagene Announces $70M Public Offering of ADSs - Boston Todaynationaltoday.com · 2026
- Adagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic | General Atlanticgeneralatlantic.com · 2020
- Adagene Raises $50 Million in Series C Fundingprnewswire.com · 2018